The U.S. Food and Drug Administration (FDA) has approved the first at-home starting dose for an Alzheimer's disease treatment, marking a significant advancement in the management of early Alzheimer's disease. The approval allows eligible patients to begin therapy using a subcutaneous (under-the-skin) injection at home, either by self-administration or with the assistance of a caregiver, reducing the need for hospital or infusion-center visits.
The approval is for Leqembi (lecanemab), jointly developed by Eisai and Biogen, for adults with early Alzheimer's disease, including those with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease, with confirmed amyloid pathology. Until now, patients initiating treatment were required to receive intravenous infusions in healthcare facilities, creating logistical challenges for many families. The newly approved subcutaneous induction regimen offers a more convenient treatment option while maintaining the same therapeutic objective of targeting amyloid-beta plaques in the brain.
The newly approved formulation enables patients to receive a once-weekly subcutaneous injection, with the initial doses administered at home. According to the companies, the injection can be completed in approximately 15 seconds using an autoinjector device. In usability studies, a large majority of patients and caregivers reported that the device was easy to use, supporting the feasibility of home-based treatment.
Leqembi belongs to a class of anti-amyloid monoclonal antibodies designed to slow the progression of Alzheimer's disease by reducing amyloid-beta plaques, one of the disease's hallmark pathological features. While the therapy does not cure Alzheimer's disease or reverse existing cognitive impairment, clinical studies have demonstrated that it can slow disease progression in appropriately selected patients when initiated during the early stages of the illness.
The FDA's latest decision may also strengthen Leqembi's competitive position in the Alzheimer's treatment market. Unlike Kisunla (donanemab), which currently requires intravenous administration, Leqembi now offers patients the flexibility of initiating therapy at home, potentially improving access and reducing the burden on healthcare systems and caregivers.
Alzheimer's disease affects millions of people worldwide, and the prevalence is expected to rise as populations age. Experts believe that making disease-modifying therapies easier to administer could improve treatment uptake, particularly among patients who face difficulties accessing specialized infusion centers. However, physicians emphasize that appropriate patient selection, diagnostic confirmation of amyloid pathology, and continued safety monitoring remain essential because anti-amyloid therapies carry risks such as amyloid-related imaging abnormalities (ARIA), requiring regular clinical evaluation.
The FDA's approval represents another milestone in the evolving treatment landscape for Alzheimer's disease, reflecting a broader shift toward therapies that are not only effective but also more convenient and accessible for patients and caregivers.
